1
|
Zhang T, He P, Guo D, Chen K, Hu Z, Zou Y. Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms. Pharmaceutics 2023; 15:1756. [PMID: 37376204 DOI: 10.3390/pharmaceutics15061756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 06/14/2023] [Accepted: 06/14/2023] [Indexed: 06/29/2023] Open
Abstract
Although hundreds of different adjuvants have been tried, aluminum-containing adjuvants are by far the most widely used currently. It is worth mentioning that although aluminum-containing adjuvants have been commonly applied in vaccine production, their acting mechanism remains not completely clear. Thus far, researchers have proposed the following mechanisms: (1) depot effect, (2) phagocytosis, (3) activation of pro-inflammatory signaling pathway NLRP3, (4) host cell DNA release, and other mechanisms of action. Having an overview on recent studies to increase our comprehension on the mechanisms by which aluminum-containing adjuvants adsorb antigens and the effects of adsorption on antigen stability and immune response has become a mainstream research trend. Aluminum-containing adjuvants can enhance immune response through a variety of molecular pathways, but there are still significant challenges in designing effective immune-stimulating vaccine delivery systems with aluminum-containing adjuvants. At present, studies on the acting mechanism of aluminum-containing adjuvants mainly focus on aluminum hydroxide adjuvants. This review will take aluminum phosphate as a representative to discuss the immune stimulation mechanism of aluminum phosphate adjuvants and the differences between aluminum phosphate adjuvants and aluminum hydroxide adjuvants, as well as the research progress on the improvement of aluminum phosphate adjuvants (including the improvement of the adjuvant formula, nano-aluminum phosphate adjuvants and a first-grade composite adjuvant containing aluminum phosphate). Based on such related knowledge, determining optimal formulation to develop effective and safe aluminium-containing adjuvants for different vaccines will become more substantiated.
Collapse
Affiliation(s)
- Ting Zhang
- Sinovac Biotech Sciences Co., Ltd., Beijing 102601, China
| | - Peng He
- Division of Hepatitis Virus & Enterovirus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102619, China
| | - Dejia Guo
- Sinovac Life Sciences Co., Ltd., Beijing 102601, China
| | - Kaixi Chen
- Sinovac Life Sciences Co., Ltd., Beijing 102601, China
| | - Zhongyu Hu
- Division of Hepatitis Virus & Enterovirus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102619, China
| | - Yening Zou
- Sinovac Life Sciences Co., Ltd., Beijing 102601, China
| |
Collapse
|
2
|
Evaluation of the Association of Recombinant Proteins NanH and PknG from Corynebacterium pseudotuberculosis Using Different Adjuvants as a Recombinant Vaccine in Mice. Vaccines (Basel) 2023; 11:vaccines11030519. [PMID: 36992103 DOI: 10.3390/vaccines11030519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 02/15/2023] [Accepted: 02/18/2023] [Indexed: 02/25/2023] Open
Abstract
Caseous lymphadenitis is a chronic contagious disease that causes economic losses worldwide. Treatments are ineffective, thus demonstrating the importance of vaccination. In this study, rNanH and rPknG proteins from Corynebacterium pseudotuberculosis were associated with saponin or aluminum hydroxide adjuvants. Three experimental groups (10 animals each) were immunized with sterile 0.9% saline solution (G1), rNanH + rPknG + Saponin (G2), rNanH + rPknG + Al(OH)3 (G3). The mice received two vaccine doses 21 days apart. Animals were challenged 21 days after the last immunization and evaluated for 50 days, with endpoint criteria applied when needed. The total IgG production levels of the experimental groups increased significantly on day 42 when compared to the control (p < 0.05). When tested against rNanH, G2 had a better rate of anti-rNanH antibodies compared to G3. In the anti-rPknG ELISA, the levels of total IgG, IgG1, and IgG2a antibodies were higher in G2. The vaccines generated partial protection, with 40% of the animals surviving the challenge. The association of recombinant NanH and PknG proteins led to promising protection rates in mice, and although using different adjuvants did not interfere with the survival rate, it influenced the immune response generated by the vaccine formulations.
Collapse
|
3
|
Barral TD, Kalil MA, Mariutti RB, Arni RK, Gismene C, Sousa FS, Collares T, Seixas FK, Borsuk S, Estrela-Lima A, Azevedo V, Meyer R, Portela RW. Immunoprophylactic properties of the Corynebacterium pseudotuberculosis-derived MBP:PLD:CP40 fusion protein. Appl Microbiol Biotechnol 2022; 106:8035-8051. [PMID: 36374330 PMCID: PMC9660185 DOI: 10.1007/s00253-022-12279-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 10/21/2022] [Accepted: 11/04/2022] [Indexed: 11/16/2022]
Abstract
Caseous lymphadenitis (CLA) is a disease that affects small ruminants, and the best way to prevent its spread on a herd is through immunoprophylaxis. Thus, we aimed to evaluate the MBP:PLD:CP40 fusion protein as a new CLA immunogen. The fusion protein was constructed by combining Corynebacterium pseudotuberculosis PLD and CP40 proteins with maltose-binding protein (MBP) as an intrinsic adjuvant. The antigenicity, allergenic potential, prediction of B epitopes, binding to MHC receptors, and docking on the Toll-Like 2 receptor were evaluated in silico. MBP:PLD:CP40 was expressed and purified. 40 BALB/c were divided into four groups (G1 - control, G2 - Saponin, G3 - MBP:PLD:CP40, and G4 - rPLD + rCP40). Total IgG, IgG1, and IgG2a were quantified, and the expressions of cytokines after splenocyte in vitro stimulation were assessed. Mice were challenged 42 days after the first immunization. The in silico analysis showed that MBP:PLD:CP40 has immunogenic potential, does not have allergic properties, and can dock on the TRL2 receptor. MBP:PLD:CP40 stimulated the production of IgG1 antibodies in a fivefold proportion to IgG2a, and TNF and IL-17 were significantly expressed in response to the antigenic stimuli. When rPLD and rCP40 were used together for immunization, they could induce IFN-γ and IL-12, but with no detectable antibody production. The G3 and G4 groups presented a survival of 57.14% and 42.86%, respectively, while the G1 and G2 mice were all dead 15 days after the challenge. MBP:PLD:CP40 partially protected the mice against C. pseudotuberculosis infection and can be considered a potential new CLA immunogen. KEY POINTS: • The fusion protein induced more IgG1 than IgG2a antibodies; • The fusion protein also induced the expression of the TNF and IL-17 cytokines; • Mice inoculated with MBP:PLD:CP40 presented a 57.14% survival.
Collapse
Affiliation(s)
- Thiago Doria Barral
- Laboratory of Immunology and Molecular Biology, Universidade Federal da Bahia, Avenida Reitor Miguel Calmon s/n, Salvador, Bahia State, 40110-100, Brazil
| | - Mauricio Alcantara Kalil
- Laboratory of Immunology and Molecular Biology, Universidade Federal da Bahia, Avenida Reitor Miguel Calmon s/n, Salvador, Bahia State, 40110-100, Brazil
| | - Ricardo Barros Mariutti
- Multiuser Center for Biomolecular Innovation, Universidade Estadual Paulista, São José do Rio Preto, São Paulo State, 15054-000, Brazil
| | - Raghuvir Krishnaswamy Arni
- Multiuser Center for Biomolecular Innovation, Universidade Estadual Paulista, São José do Rio Preto, São Paulo State, 15054-000, Brazil
| | - Carolina Gismene
- Multiuser Center for Biomolecular Innovation, Universidade Estadual Paulista, São José do Rio Preto, São Paulo State, 15054-000, Brazil
| | - Fernanda Severo Sousa
- Center for Technological Development, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul State, 96010-900, Brazil
| | - Tiago Collares
- Center for Technological Development, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul State, 96010-900, Brazil
| | - Fabiana Kommling Seixas
- Center for Technological Development, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul State, 96010-900, Brazil
| | - Sibele Borsuk
- Center for Technological Development, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul State, 96010-900, Brazil
| | - Alessandra Estrela-Lima
- Laboratory of Veterinary Pathology, School of Veterinary Medicine and Zootechnics, Universidade Federal da Bahia, Salvador, Bahia State, 40110-100, Brazil
| | - Vasco Azevedo
- Laboratory of Molecular and Cellular Genetics, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais State, 31270-901, Brazil
| | - Roberto Meyer
- Laboratory of Immunology and Molecular Biology, Universidade Federal da Bahia, Avenida Reitor Miguel Calmon s/n, Salvador, Bahia State, 40110-100, Brazil
| | - Ricardo Wagner Portela
- Laboratory of Immunology and Molecular Biology, Universidade Federal da Bahia, Avenida Reitor Miguel Calmon s/n, Salvador, Bahia State, 40110-100, Brazil.
| |
Collapse
|